News | ASTRO | October 22, 2020

ASTRO Responds to CMS Announcement on Delayed Radiation Oncology Model Start Date

On Oct. 21, Seema Verma, administrator of the Centers for Medicare & Medicaid Services, tweeted that CMS will delay the Radiation Oncology Model’s launch from Jan. 1 to July 1 

On Oct. 21, Seema Verma, administrator of the Centers for Medicare & Medicaid Services, tweeted that CMS will delay the Radiation Oncology Model’s launch from Jan. 1 to July 1 

Getty Images

October 22, 2020 — In response to the Oct. 21 announcement that the Centers for Medicare and Medicaid Services (CMS) will delay the start date for the Radiation Oncology Model from Jan. 1 to July 1, 2021, the American Society for Radiation Oncology (ASTRO) issued the following statement from Theodore L. DeWeese, M.D., FASTRO, Chair of the ASTRO Board of Directors:

"ASTRO appreciates today’s announcement by CMS Administrator Seema Verma that CMS will delay the Radiation Oncology Model launch from January 1, 2021 until July 1, 2021 based on feedback from ASTRO and other radiation oncology stakeholders. This change is an important recognition of the radiation oncology community’s concerns, and we are pleased and thankful that Administrator Verma listened to the needs of our member radiation oncology practices during these challenging times.

We are hopeful that the delay represents the first step toward full, open engagement with ASTRO on ways to ensure that the RO Model achieves our shared goals of higher quality, lower cost cancer care. We remain seriously concerned with excessive payment cuts in the model that will cause significant financial strain on practices and risk patient access to radiation treatments.

ASTRO is committed to a successful alternative payment model for radiation oncology, and we look forward to working with CMS during the delay period to ensure that the concerns of ASTRO and its more than 10,000 members, as well as cancer patients, members of Congress and other radiation oncology stakeholders are addressed."

For more informaton: www.astro.org

Related Content

#SiemensHealthineers #Varian #Siemens The transformative combination accelerates the company’s impact on #global #healthcare and establishes a strong partner for #customers and #patients along the entire #cancer care continuum and for many of the most threatening #diseases
News | Radiology Business | April 15, 2021
April 15, 2021 — Siemens Healthineers AG an
The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
Futuristic campus design of Siemens Healthineers in Bengaluru, India.

Futuristic campus design of Siemens Healthineers in Bengaluru, India.

News | Radiology Business | April 08, 2021
April 8, 2021 — Siemens Healthineers announced t
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.
News | Women's Health | April 08, 2021
April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage F
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
Elsevier’s STATdx, a leading radiology diagnostic decision support solution, now includes select Merit-Based Incentive Payment System (MIPS) Measures validated by MDinteractive
News | Clinical Decision Support | April 02, 2021
April 2, 2021 — Elsevier, a global leader in research publishing and information analytics, announced a partnership w
The National Comprehensive Cancer Network® (NCCN®) and the American Cancer Society (ACS) are teaming up with leading health organizations across the country to endorse the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
News | Radiation Therapy | March 31, 2021
March 31, 2021 — Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanc
Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Lung Imaging | March 29, 2021
March 29, 2021 — According to ARRS'